Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries
- Imperial College London, Switzerland
- London School of Hygiene & Tropical Medicine, United Kingdom
- University of Notre Dame, France
- University of Cambridge, United Kingdom
- Institute for Disease Modelling, United States
- Imperial College London, United Kingdom
- Pennsylvania State University, United States
- Kaiser Permanente Washington,, United States
- University of Notre Dame, United States
Abstract
Background: Childhood immunisation services have been disrupted by COVID-19. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns during the pandemic.
Methods: We used 2-3 models per infection to estimate the health impact of 50% reduced routine vaccination coverage and delaying campaign vaccination for measles, meningococcal A and yellow fever vaccination in 3-6 high burden countries per infection.
Results: Reduced routine coverage in 2020 without catch-up vaccination may increase measles and yellow fever disease burden in the modelled countries. Delaying planned campaigns may lead to measles outbreaks and increases in yellow fever burden in some countries. For meningococcal A vaccination, short term disruptions in 2020 are unlikely to have a significant impact.
Conclusion: The impact of COVID-19-related disruption to vaccination programs varies between infections and countries.
Funding: Bill and Melinda Gates Foundation and Gavi, the Vaccine Alliance.
Data availability
All code, data inputs and outputs used to generate the results in the manuscript (apart from projections about vaccine coverage beyond 2020 which are commercially confidential property of Gavi) are available at: https://github.com/vimc/vpd-covid-phase-I.
Article and author information
Author details
Katy A M Gaythorpe
Funding
Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation (OPP1157270 and INV-016832)
- Katy A M Gaythorpe
- Kaja Abbas
- John Huber
- Andromachi Karachaliou
- Niket Thakkar
- Kim Woodruff
- Xiang Li
- Susy Echeverria-Londono
- Matthew Ferrari
- Michael Jackson
- Kevin McCarthy
- Alex T Perkins
- Caroline Trotter
- Mark Jit
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2021, Gaythorpe et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,806
- views
-
- 372
- downloads
-
- 52
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries
eLife 10:e67023.
https://doi.org/10.7554/eLife.67023
Further reading
-
- Epidemiology and Global Health
- Evolutionary Biology
Several coronaviruses infect humans, with three, including the SARS-CoV2, causing diseases. While coronaviruses are especially prone to induce pandemics, we know little about their evolutionary history, host-to-host transmissions, and biogeography. One of the difficulties lies in dating the origination of the family, a particularly challenging task for RNA viruses in general. Previous cophylogenetic tests of virus-host associations, including in the Coronaviridae family, have suggested a virus-host codiversification history stretching many millions of years. Here, we establish a framework for robustly testing scenarios of ancient origination and codiversification versus recent origination and diversification by host switches. Applied to coronaviruses and their mammalian hosts, our results support a scenario of recent origination of coronaviruses in bats and diversification by host switches, with preferential host switches within mammalian orders. Hotspots of coronavirus diversity, concentrated in East Asia and Europe, are consistent with this scenario of relatively recent origination and localized host switches. Spillovers from bats to other species are rare, but have the highest probability to be towards humans than to any other mammal species, implicating humans as the evolutionary intermediate host. The high host-switching rates within orders, as well as between humans, domesticated mammals, and non-flying wild mammals, indicates the potential for rapid additional spreading of coronaviruses across the world. Our results suggest that the evolutionary history of extant mammalian coronaviruses is recent, and that cases of long-term virus–host codiversification have been largely over-estimated.
-
- Cancer Biology
- Epidemiology and Global Health
Cancer is considered a risk factor for COVID-19 mortality, yet several countries have reported that deaths with a primary code of cancer remained within historic levels during the COVID-19 pandemic. Here, we further elucidate the relationship between cancer mortality and COVID-19 on a population level in the US. We compared pandemic-related mortality patterns from underlying and multiple cause (MC) death data for six types of cancer, diabetes, and Alzheimer’s. Any pandemic-related changes in coding practices should be eliminated by study of MC data. Nationally in 2020, MC cancer mortality rose by only 3% over a pre-pandemic baseline, corresponding to ~13,600 excess deaths. Mortality elevation was measurably higher for less deadly cancers (breast, colorectal, and hematological, 2–7%) than cancers with a poor survival rate (lung and pancreatic, 0–1%). In comparison, there was substantial elevation in MC deaths from diabetes (37%) and Alzheimer’s (19%). To understand these differences, we simulated the expected excess mortality for each condition using COVID-19 attack rates, life expectancy, population size, and mean age of individuals living with each condition. We find that the observed mortality differences are primarily explained by differences in life expectancy, with the risk of death from deadly cancers outcompeting the risk of death from COVID-19.
